Clinical Trial Nuedexta in Subjects With ALS

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
DRUG

Nuedexta

Nuedexta PO (by mouth) for 28 ± 3 days

DRUG

Matching Placebo

matching placebo PO (by mouth) for 28 ± 3 days

Trial Locations (7)

20007

Georgetown University Medical Center, Washington D.C.

44195

The Cleveland Clinic, Cleveland

49503

Saint Mary's Health Care, Grand Rapids

55415

Hennepin County Medical Center, Minneapolis

68506

Neurology Associates, P.C., Lincoln

94115

California Pacific Medical Center, San Francisco

97213

Providence ALS Center, Portland

All Listed Sponsors
collaborator

ALS Association

OTHER

collaborator

State University of New York - Upstate Medical University

OTHER

lead

Center for Neurologic Study, La Jolla, California,

OTHER

NCT01806857 - Clinical Trial Nuedexta in Subjects With ALS | Biotech Hunter | Biotech Hunter